サンプル依頼リスト カート
  • English
  • Korean
表紙：帯状疱疹感染症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1345383

帯状疱疹感染症治療の世界市場-2023年～2030年

Global Herpes Zoster Infection Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
帯状疱疹感染症治療の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

帯状疱疹感染症治療の世界市場は、2022年に2億5,120万米ドルに達し、2023～2030年の予測期間中にCAGR 3.6%で成長し、2030年には3億3,100万米ドルに達すると予測されています。

ラムゼイ・ハント症候群は、耳性帯状疱疹としても知られる帯状疱疹関連疾患で、片方の耳の周りの顔面神経が侵されます。これは水痘帯状疱疹ウイルスによって誘発される神経疾患です。このウイルスは、水ぼうそうや帯状疱疹を引き起こすウイルスと同一です。この疾患は男性も女性も同様に罹患します。顔面神経麻痺を引き起こし、顔の片側に苦痛、水疱、じんましんが生じます。

この疾患はあらゆる世代の人に影響を及ぼしますが、高齢者ではさらに馴染みが深いです。さらに、不快感、じんましん、顔面神経麻痺、味覚障害、聴力障害、耳鳴り、めまい、嗄声、構音障害などを呈し、ラムゼイ・ハント症候群の短期的な込み入った症状としては、角膜擦過傷および暴露角膜症、うつ病、社会的神経過敏、免疫のない、あるいは免疫不全の直系血縁者への水痘感染などがあります。

長期の弛緩性麻痺はありえませんが、シニキネシスの結果は非常に典型的です。その他、帯状疱疹後神経痛、小水疱の瘢痕化、顔面機能の障害による絶望や社会不安の継続など、長期にわたる複雑な症状があります。その他の要因の中でも、このような希少疾患に対する研究活動、認識、支援イニシアチブの増加が、予測期間中の世界市場の成長を押し上げると予想されます。

市場力学

調査研究の増加

調査研究の増加は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、Solve M.E.は、ME/CFSとLong Covidの根本的な理由の調査に資金を提供しています。Ramsay Research Grant Programは、試験的な調査やデータ研究に資金を提供するための補助金を募る無制限の査読付きコンペティションです。ラムジー・プログラムは、ME/CFSの領域に新たな研究者を引き込むことで活況を呈しており、この疾患の科学に取り組み、パイロットデータを作成する研究者に多くの助成金を提供しています。

例えば、2016年以降、34の研究がラムジー助成金によって資金提供されています。ラムゼイ・プログラムに関心を持つ91人以上の調査協力者のネットワークがあります。これらのプロジェクトの主任研究者の50％以上が、初めてME/CFSの調査に専門知識を応用し、17のプロジェクトが初期キャリア段階の研究者に関心を寄せています。NINDSは、帯状疱疹および帯状疱疹関連疾患に関する調査を後援しています。最近の研究では、単純ヘルペスウイルスや水痘帯状疱疹ウイルスを含む神経栄養性ウイルスの持続と神経疾患の成長との関連に集中しています。したがって、これらの研究の助けを借りて、研究者はこの希少疾患を治療するための新しい治療法を発見しており、これが市場の成長を高めています。

希少疾患に対する取り組みの増加

希少疾患に対する取り組みの増加も、予測期間中の世界市場の成長に寄与しています。例えば、2023年5月、多国籍の価値観に基づくR&D主導のバイオ医薬品トップ企業である武田バイオファーマシューティカルズ・インディア・プライベート・リミテッド（以前はバクサルタ・バイオサイエンス・インディア・プライベート・リミテッドとして理解されていた）は、インドにおける希少疾患（RD）の保健システムを支援する一般的な保健イニシアチブの普及を主導しました。

さらに、2023年7月、FDAは、希少疾患を治療する未踏のFDAグレードの有効性エンドポイントの成長を維持するユニークなパイロットプログラムに参加する企業や利害関係者からの申請を受け付け始めました。希少疾患エンドポイントアドバンスメント（RDEA）パイロットプログラムは、医薬品評価研究センター（CDER）と生物製剤評価研究センター（CBER）の共同努力として2022年10月に開始されました。

誤診の多い疾患

ラムゼイ・ハント症候群の診断の難しさは、予測期間中の世界市場の成長を妨げると予想されます。ラムゼイ・ハント症候群の症状は個人によって異なるためです。罹患者は一般的に、顔面神経の麻痺と耳に影響を及ぼす発疹に遭遇します。これら2つの症状は、常に同じ瞬間に現れるわけではありません。大半の患者では、顔の片側のみに影響が出ます。

診断は、包括的な臨床評価、綿密な患者記録、および典型的な症状（すなわち、片側の顔面神経麻痺および/または耳周囲の発疹）の同定に基づいて確立されます。診断の確定には、耳を取り囲む液体で満たされた水疱性発疹の代表的なものを利用することができます。これらのじんましんは、ベル麻痺、音響神経腫、三叉神経痛ではなく、ラムゼイ・ハント症候群であることを示す有効な指標です。英国顔面神経麻痺協会（Facial Palsy UK）が英国のRHS患者206人を対象に行った調査では、RHS患者の50%以上がベル麻痺と誤診されていました。

世界の有病率の低さ

世界の耳帯状疱疹またはラムゼイ・ハント症候群の有病率・検出率の低さは、予測期間中に世界の帯状疱疹感染症治療市場の成長を減速させると予想されるもう一つの要因です。例えば、帯状疱疹患者の1％未満が顔面神経を巻き込み、ラムゼイ・ハント症候群を発症します。RHSは、水痘や帯状疱疹ウイルスに関連し、顔面脱力や麻痺を引き起こす極めてまれなウイルス性疾患です。

ラムゼイ・ハント症候群は、臨床的に分析されたベル麻痺と診断された患者のわずか20％の原因であると考えられています。さらに、VZVによって誘発された顔面神経麻痺の自然寛解は少数の症例にしか現れず、適切な治療を行わなければ、わずか20％しか完全回復に至りません。さらに、認知度の低さが診断率の低さにつながっており、これが世界の有病率の低さにつながっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 調査件数の増加
      • 希少疾患に対する取り組み強化
    • 抑制要因
      • 疾患の頻繁な誤診
      • 世界的に低い有病率
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 疫学統計
  • 価格分析
  • 規制分析
  • 特許分析
  • パイプライン分析
  • SWOT分析
  • DMIの見解

第6章 COVID-19分析

第7章 治療タイプ別

  • 処方薬
    • 抗ウイルス剤
    • 鎮痛剤
      • 非ステロイド性抗炎症薬
      • オピオイド
    • ステロイド
  • 補助療法
    • 点眼薬

第8章 投与経路別

  • 経口
  • 静脈内投与
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • GSK plc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • BAUSCH HEALTH COMPANIES INC.
  • Renata Limited
  • Novan, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Pfizer Inc.
  • Apotex Inc.
  • Sandoz Canada Inc.
  • Novartis Pharmaceuticals Corporation
  • Cipla

第13章 付録

目次
Product Code: PH4601

Market Overview

Global Herpes Zoster infection treatment market reached US$ 251.2 million in 2022 and is expected to reach US$ 331.0 million by 2030, growing with a CAGR of 3.6% during the forecast period 2023-2030.

Ramsay Hunt Syndrome, also known as herpes zoster oticus, is a shingles-related disorder in which the facial nerve around one of the ears is involved. This is a neurological disorder that is induced by the varicella-zoster virus. The virus is identical to the one that provokes chicken pox and shingles. The condition affects both males and females equally. It induces facial paralysis, resulting in distress, blisters, and hives on one side of the face.

This condition impacts individuals of all generations, but it is additionally familiar in the elderly. Further, presenting manifestations include discomfort, hives, facial paralysis, dysgeusia, hearing failure, tinnitus, dizziness, hoarseness, dysarthria, and others, short-term intricacies of Ramsay Hunt Syndrome include corneal graze and exposure keratopathy, depression, and social nervousness, and transmission of chickenpox to unimmunized or immunocompromised immediate connections.

While long-term flaccid paralysis is improbable, the consequence of synkinesis is very typical. Other long-term intricacies enclose postherpetic neuralgia, scarring from the vesicles, and continuous despair and/or social anxiety due to failure of facial function. The increasing research activities, awareness and support initiatives for such rare disorders among other factors are expected to boost the global market growth during the forecast period.

Market Dynamics

Increasing Number of Research Studies

The Increasing Research Studies are expected to boost the global market growth during the forecast period. For instance, the Solve M.E. funds investigation into the underlying reasons for ME/CFS and Long Covid via the Ramsay Research Grant Program, an unrestricted, peer-reviewed competition for subsidies to fund pilot investigations and data research. The Ramsay Program has been booming in drawing new researchers to the domain of ME/CFS, delivering much-required grants for investigators to engage with the science of the condition and produce pilot data.

For instance, since 2016, 34 investigations have been funded by Ramsay Grants. There is a network of more than 91 investigation collaborators who have been interested in the Ramsay Program. More than 50% of the chief researchers on these projects applied their expertise to investigate ME/CFS for the foremost time and 17 of the projects interested early-career phase investigators. The NINDS sponsors an investigation on shingles and shingles-related disorders. Recent investigations concentrate on the association between the perseverance of neurotropic viruses and the growth of neurological conditions enclosing herpes simplex and varicella-zoster viruses. Hence, with the help of these studies, researchers are finding novel treatment methodolgies to treat this rare disease which is enhanceing the market growth.

Increasing Initiatives for Rare Disease

The increasing initiatives to fight against rare disorders are also contributing to the global market growth during the forecast period. For instance, in May 2023, Takeda Biopharmaceuticals India Private Limited (previously comprehended as Baxalta Bioscience India Private Limited), a multinational values-based, R & D-driven biopharmaceutical top corporation led the dissemination of its general health initiatives in supporting the health system for rare diseases (RD) in India.

Moreover, in July 2023, the FDA started receiving submissions from enterprises and stakeholders to partake in a unique pilot program sustaining the growth of unexplored FDA-grade effectiveness endpoints to treat rare disorders. The Rare Disease Endpoint Advancement (RDEA) Pilot Program was launched in October 2022 as a collaborative endeavor between the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

Frequent Misdiagnosis of the Condition

The difficulty in diagnosis of the Ramsy Hunt Syndrome is expected to hamper the global market growth during the forecast period. As the manifestations of Ramsay Hunt Syndrome differ from individual to individual. Affected people generally encounter paralysis of the facial nerve and a rash impacting the ear. These two manifestations do not consistently appear at the identical moment. In the majority of individuals, solely one side of the face is impacted.

Diagnosis is established on a comprehensive clinical evaluation, exhaustive patient record, and identification of typical manifestations (i.e., one-sided facial palsy and/or a rash around the ear). A representative from the fluid-filled blistering rash encircling the ear can be utilized to establish the diagnosis. These hives are a valid indicator that the condition is Ramsay Hunt Syndrome and not Bell's palsy, acoustic neuroma, or trigeminal neuralgia. In a survey of 206 RHS patients in the UK, Facial Palsy UK encountered that above 50% of those with RHS had been originally misdiagnosed as retaining Bell's palsy.

Low Prevalence of the Condition Globally

The low global prevalence and detection of Herpes Zoster Oticus or Ramsy Hunt Syndrome is another factor that is expected to slow the global herpes zoster infection treatment market growth during the forecast period. For instance, in less than 1% of zoster patients involve the facial nerve and develop Ramsay Hunt Syndrome. RHS is an extremely rare viral disorder that is associated with chickenpox and the shingles virus that leads to facial weakness or paralysis.

Ramsay Hunt Syndrome is believed to be the reason behind only 20% of clinically analyzed patients diagnosed with Bell palsy. Additionally, the spontaneous remission of the facial palsy induced by VZV appears only in a small number of cases, without the appropriate treatment, just 20% reach full recovery. Further, the lack of awareness leads to low rate of diagnosis which again add-up to the low prevalence of the condition globally.

Segment Analysis

The Global Herpes Zoster Infection Treatment Market is segmented based on treatment type, route of administration, distribution channel and region.

Antiviral Drugs to Dominate the Market

Antiviral therapy is solely efficacious against virus reproduction in herpes zoster infections that is, it can contain additional multiplication and spread of the varicella-zoster virus but cannot eliminate the viruses. Oral antiviral therapy has been considered in the therapy of herpes zoster infections in other parts of the body and has been ascertained by studies to reduce the stringency of herpes zoster infection in immunocompromised adults.

Further, it lowers the period of viral shedding and new lesion appearance, thereby increasing the rash healing rate and lessening the duration of pain and thus are considered to be the first line of treatment against Ramsay Hunt Syndrome. The most typically prescribed antivirals for Ramsay Hunt Syndrome include Zovirax, Famvir, and Valtrex. Antiviral medications have been comprehended to induce side effects like headaches and dizziness.

Geographical Penetration

Increasing Number of Herpes Zoster Cases in North America dominates the region

With the increasing cases of Ramsay Hunt Syndrome in North America and the presence of the most advanced healthcare infrastructure North America is expected to hold around 43.2% most of the global market share throughout the forecast period. For instance, according to the National Organization for Rare Disorders, Ramsay Hunt Syndrome impacts approximately 5 out of every 100,000 individuals annually in the U.S. Nevertheless, most researchers believe the disorder is periodically undiagnosed or misdiagnosed. This creates difficulty to determine its frequency.

The condition is among the second most highly typical reason for facial nerve paralysis, making up for over 7% of all patients. Ramsay Hunt Syndrome transpires when the varicella-zoster virus reactivates in the facial nerve, which is the cranial nerve that involves the face, tongue, and inner ear. Therefore, the growing cases of the varicella-zoster virus demonstrate the expanded preponderance of the infection in this region. For instance, according to the CDC, roughly one out of three individuals in the United States are expected to develop herpes zoster during their lifetime. Many individuals have only one attack, nonetheless, herpes zoster can recur.

COVID-19 Impact Analysis

Varicella-zoster virus reactivation and idiopathic facial paralysis have frequently been documented in connection with a few virus vaccinations, such as influenza and hepatitis B. It is thus not quite unexpected that patients of both conditions concerning SARS-CoV-2 vaccination have lately been publicized. Evidence of peripheral facial paralysis has even appeared from a phase III clinical trial with COVID-19 vaccines.

Nevertheless, no other documented cases of Ramsay-Hunt syndrome heeding COVID-19 vaccination or any other virus vaccination in the recent publications. This is presumably because herpes zoster accounts for shorter than 1% of all patients of herpes zoster and only 12% of peripheral facial paralysis cases, whose potential connections with vaccines are already infrequent. Thus, the COVID-19 is estimated to have very minimal imapct over the global market.

By Treatment Type

  • Prescription Treatment

Antivirals

Painkillers

  • NSAIDs
  • Opioids

Steroids

  • Supporting Treatment

Ophthalmic Solutions

By Route of Administration

  • Oral
  • Intravenous
  • Other

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

UK

France

Italy

Spain

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • In June 2023, GlaxoSmithKline (GSK) obtained the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for a renewed indication of its shingles (herpes zoster) vaccine, Shingrix, a recombinant zoster vaccine, adjuvanted [RZV)].
  • In February 2023, Pfizer Inc. and BioNTech SE began a Phase I/II trial for the parties' mRNA vaccines for shingles (Herpes Zoster), for which there is no presently authorized vaccine. The multicenter, randomized, managed, dose-selection investigation intended to assess the safety, tolerability, and immunogenicity of mRNA vaccine nominees against shingles.

Competitive Landscape

The major global players in the market include GSK plc., BAUSCH HEALTH COMPANIES INC., Teva Pharmaceuticals USA, Inc., Pfizer Inc., Apotex Inc., Sandoz Canada Inc., Novartis Pharmaceuticals Corporation, and Cipla among others.

Why Purchase the Report?

  • To visualize the Global Herpes Zoster Infection Treatment Market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Herpes Zoster Infection Treatment Market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The Global Herpes Zoster Infection Treatment Market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Number of Research Studies
      • 4.1.1.2. Increasing Initiatives for Rare Disease
    • 4.1.2. Restraints
      • 4.1.2.1. Frequent Misdiagnosis of the Condition
      • 4.1.2.2. Low Prevalence of the Condition Globally
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Epidemiology Stats
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Patent Analysis
  • 5.7. Pipeline Analysis
  • 5.8. SWOT Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Prescription Treatment*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Antivirals
    • 7.2.4. Painkillers
      • 7.2.4.1. NSAIDs
      • 7.2.4.2. Opioids
    • 7.2.5. Steroids
  • 7.3. Supporting Treatment
    • 7.3.1. Ophthalmic Solutions

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous
  • 8.4. Other

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospitals Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GSK plc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. BAUSCH HEALTH COMPANIES INC.
  • 12.3. Renata Limited
  • 12.4. Novan, Inc.
  • 12.5. Teva Pharmaceuticals USA, Inc.
  • 12.6. Pfizer Inc.
  • 12.7. Apotex Inc.
  • 12.8. Sandoz Canada Inc.
  • 12.9. Novartis Pharmaceuticals Corporation
  • 12.10. Cipla

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us